Physician profile
Jay C Koons
NPI 1942237714
$7,972.67
in general payments reported to CMS, 2019-2025
37 companies · $843 in 2025
The $843 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,210 · 2020: $1,056 · 2021: $1,392 · 2022: $477 · 2023: $1,260 · 2024: $735 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464 · Travel and Lodging: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.76 |
| Travel and Lodging | $374.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,210.77 | 2019-2021 | |
| Medtronic Vascular, INC. | $1,149.17 | 2019 | |
| Abiomed | $844.95 | 2019-2023 | Impella |
| Janssen Research & Development, LLC | $664.58 | 2023 | |
| Boston Scientific Corporation | $469.83 | 2019-2024 | Watchman Flx |
| Amgen INC. | $450.15 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $359.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.54 | 2020-2025 | Jardiance |
| Penumbra, INC. | $227.50 | 2019-2025 | Indigo System |
| Cvrx, INC. | $187.86 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $176.14 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $160.94 | 2023-2025 | |
| Recor Medical INC | $149.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shockwave Medical, INC | $148.97 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $144.26 | 2019-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $140.79 | 2021 | |
| Pfizer INC. | $139.04 | 2022-2024 | |
| Medtronic, INC. | $131.25 | 2024 | Onyx Frontier |
| Regeneron Healthcare Solutions, INC. | $124.82 | 2019-2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $121.34 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $108.38 | 2022-2024 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $72.68 | 2020-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $72.00 | 2023 | Arcalyst |
| Acist Medical Systems, INC. | $66.06 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $64.78 | 2023-2024 | Inpefa |
| Silk Road Medical, INC. | $50.29 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Livanova USA, INC. | $48.29 | 2022 | |
| Ge Healthcare | $35.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.39 | 2019 | |
| Scpharmaceuticals INC. | $24.74 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.73 | 2019-2023 | Lifevest |
| Bridgebio Pharma, INC. | $23.30 | 2025 | Attruby |
| Organogenesis INC. | $20.54 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.94 | 2024 | Arcalyst |
| Novo Nordisk INC | $16.52 | 2023 | Rybelsus, Ozempic |
| Kerecis Limited | $13.57 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Lundbeck LLC | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Koons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.